Innate Pharma SA — FY 2023 Form 20-F Summary
Reporting period: Fiscal year ended December 31, 2023. Although the request refers to 2023 Q4, this is an annual report, not a standalone quarterly filing; the supplied text does not provide standalone Q4 financial results. Financial statements are audited and prepared under IFRS as issued by the IASB, in euros. The filing was signed April 4, 2024.
Business context
Innate Pharma is a clinical-stage biotechnology company developing cancer immunotherapies. Its portfolio includes proprietary lacutamab and ANKET programs and partnered programs with AstraZeneca and Sanofi; it also entered a licensing agreement with Takeda in 2023. The company has no commercial product revenue of significance and depends substantially on collaboration income, French research tax credits and external financing.
Financial performance and liquidity
| Metric | FY 2023 | FY 2022 |
|---|---|---|
| Collaboration and licensing revenue | €51.9m | €49.6m |
| Government research funding, primarily tax credits | €9.7m | €8.0m |
| Total revenue and other income | €61.6m | €57.7m |
| Research and development expense | €56.0m | €51.7m |
| General and administrative expense | €18.3m | €22.4m |
| Operating loss | €12.7m | €57.4m |
| Net loss | €7.6m | €58.1m |
| Net cash used in operating activities | €32.6m | €19.2m |
| Cash and cash equivalents | €70.6m | €84.2m |
| Cash, cash equivalents and short-term investments | €92.5m | €101.5m |
| Cash, cash equivalents, short-term and non-current financial assets | €102.3m | €136.6m |
Operating expenses fell to €74.3m from €115.1m, primarily because the prior year included a €41.0m impairment of avdoralimab rights. The 2023 net loss also benefited from €5.1m net financial income, versus a €0.5m net financial loss in 2022. Research and development expense increased 8.4%; G&A expense decreased 18.5%. No income tax expense was recorded.
Operating cash outflow increased by €13.4m. The company attributed this mainly to working-capital movements and timing of collaboration and tax-credit receipts; excluding specified exceptional receipts and payments, management said operating cash use decreased by €5.5m. Investing cash flow was positive €20.6m, mainly from disposal of a non-current financial instrument (€22.8m), rather than operating cash generation. Cash and cash equivalents declined €13.6m during the year.
Financial liabilities were €39.9m at year-end, including €28.7m of state-guaranteed loans and approximately €10.2m remaining on the Société Générale building loan. Contractual principal and interest payments total €41.6m, including lease obligations. The building loan is secured by €15.2m of pledged financial instruments and includes a minimum-liquidity covenant; the company reported compliance at year-end. The €28.7m state-guaranteed loans begin amortizing in 2024.
Material changes versus prior year
- Total revenue and other income rose €4.0m, but mix changed materially. 2023 included Sanofi collaboration and option revenue and a Takeda upfront license payment; 2022 included €17.4m recognized after AstraZeneca declined options on four preclinical programs and a €4.7m IPH5201 milestone.
- Monalizumab revenue declined €12.9m to €9.5m, largely because 2022 included a cumulative revenue adjustment following the PACIFIC-9 milestone. Monalizumab collaboration liabilities fell €10.5m to €52.7m.
- Research and development spending rose €4.4m, mainly from preclinical programs, including ADC work; G&A spending fell €4.1m following cost reductions and lower staffing.
- The net loss narrowed by €50.5m, chiefly because the €41.0m avdoralimab impairment recorded in 2022 did not recur, alongside higher collaboration revenue and improved net financial results.
- Cash used in operations increased, while cash and short-term investments fell €9.0m. The investing cash inflow was largely due to liquidation of a non-current financial instrument.
Outlook, programs and notable events
- Management expects continued losses and says further funding will be needed before clinical development is completed. The filing states in one section that available resources are expected to fund operations for at least two years, but elsewhere says at least 12 months; the difference is not reconciled in the supplied text.
- Collaboration and licensing agreements are expected to remain a major revenue source. Upfront and milestone receipts are uncertain and depend on clinical, regulatory and partner decisions. The filing cites substantial contingent milestone opportunities, but these are not assured proceeds.
- Lacutamab: final 2023 TELLOMAK Sézary syndrome results showed a confirmed global response rate of 37.5% (21/56), median progression-free survival of 8.0 months and median response duration of 12.3 months among responders. Final mycosis fungoides results were expected in 2024. A U.S. FDA partial clinical hold imposed in October 2023 after a fatal HLH case was lifted in January 2024; the company and independent experts assessed the death as related to disease progression and not lacutamab. The company-sponsored PTCL monotherapy study will not resume enrollment after failing its prespecified activity threshold; an investigator-sponsored combination study continues.
- Monalizumab: AstraZeneca’s Phase 3 INTERLINK-1 head-and-neck study was discontinued after failing a prespecified efficacy threshold; later results showed no improvement in overall or progression-free survival versus control. The PACIFIC-9 Phase 3 lung cancer study and other lung cancer trials were ongoing at the time described.
- Other pipeline activity includes the MATISSE Phase 2 study of IPH5201 in early-stage lung cancer, Sanofi-sponsored ANKET clinical programs and the proprietary IPH6501 program. The first IPH6501 patient was dosed in March 2024, after year-end.
- Sanofi exercised an option on an additional ANKET program in December 2023; the associated €15m payment was received in January 2024. Takeda’s 2023 ADC license generated a $5m upfront payment, with up to $410m in contingent milestones plus potential royalties.
- CEO Mondher Mahjoubi resigned effective December 31, 2023. Co-founder Hervé Brailly became interim CEO while a permanent successor was sought; two additional Executive Board members were appointed in January 2024.
- Risks include clinical and regulatory failure, patient recruitment, dependence on collaborators and third-party manufacturing, financing needs, competition, intellectual-property disputes, foreign-exchange exposure and French research-tax-credit eligibility. The company reported no legal proceeding it believed likely to have a material adverse effect. It reported internal-control effectiveness at December 31, 2023 and remediation of the prior-year material weakness; the auditor did not provide an internal-control attestation because of the company’s emerging-growth-company status.
Most important facts for investors to verify
- Reconcile the filing’s differing runway statements (at least 12 months versus two years) with expected cash burn, committed trial costs and the timing of partner and tax-credit receipts.
- Confirm the fully diluted share count and year-end outstanding shares: the cover page reports 80,453,282 ordinary shares, while the financial statements report 80,874,653 total shares and the share-capital note gives a different ordinary-share count, alongside treasury shares and potential equity awards.
- Track 2024 lacutamab mycosis fungoides final results and safety updates, and distinguish the discontinued PTCL monotherapy program from the ongoing investigator-sponsored combination trial.
- Monitor PACIFIC-9 progress and any further monalizumab data after INTERLINK-1 failed its efficacy threshold; confirm the scope and timing of any future AstraZeneca milestones or royalties.
- Assess the quality and repeatability of 2023 collaboration revenue, including upfront and option-related items, and whether new milestones can offset operating cash use.
- Review state-guaranteed loan amortization beginning in 2024, the €15.2m pledged collateral and minimum-liquidity covenant, and the availability and timing of the 2023 French research tax credit.